Boston Scientific Corp [BSX] stock Upgrade by Oppenheimer analyst, price target now $125

Misty Lee

Boston Scientific Corp [NYSE: BSX] stock went on a downward path that fall over -2.77% on Monday, amounting to a one-week price decrease of less than -7.65%.

Over the last 12 months, BSX stock rose by 11.81%. The one-year Boston Scientific Corp stock forecast points to a potential upside of 20.55. The average equity rating for BSX stock is currently 1.28, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $147.98 billion, with 1.48 billion shares outstanding and 1.48 billion shares in the current float. Compared to the average trading volume of 7.12M shares, BSX stock reached a trading volume of 12003419 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Boston Scientific Corp [BSX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $125.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.28. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for Boston Scientific Corp shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 08, 2025. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on June 16, 2025, representing the official price target for Boston Scientific Corp stock. Previously, the target price had yet another raise to $113, while Needham analysts kept a Buy rating on BSX stock.

The Price to Book ratio for the last quarter was 6.59, with the Price to Cash per share for the same quarter was set at 0.43. Price to Free Cash Flow for BSX in the course of the last twelve months was 42.46 with Quick ratio for the last quarter at 0.82.

BSX Stock Performance Analysis:

Boston Scientific Corp [BSX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.65. With this latest performance, BSX shares dropped by -4.11% in over the last four-week period, additionally plugging by 2.79% over the last 6 months – not to mention a rise of 11.81% in the past year of trading.

Insight into Boston Scientific Corp Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corp [BSX] shares currently have an operating margin of 16.66% and a Gross Margin at 61.90%. Boston Scientific Corp’s Net Margin is presently recorded at 13.55%.

Boston Scientific Corp (BSX) Capital Structure & Debt Analysis

According to recent financial data for Boston Scientific Corp. ( BSX), the Return on Equity (ROE) stands at 11.71%, reflecting robust shareholder value creation. The Return on Assets (ROA) is 6.37%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Boston Scientific Corp’s Return on Invested Capital (ROIC) is 7.38%, showcasing its effectiveness in deploying capital for earnings.

Boston Scientific Corp (BSX) Efficiency & Liquidity Metrics

Based on Boston Scientific Corp’s (BSX) latest financial statements, the Debt-to-Equity Ratio is 0.54%, indicating its reliance on debt financing relative to shareholder equity.

Boston Scientific Corp (BSX) Efficiency & Liquidity Metrics

From an operational efficiency perspective, Boston Scientific Corp. (BSX) effectively leverages its workforce, generating an average of $47358.49 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.37% and a Quick Ratio of 0.82%, indicating strong ability to cover short-term liabilities.

BSX Stock EPS

With the latest financial reports released by the company, Boston Scientific Corp posted 0.63/share EPS, while the average EPS was predicted by analysts to be reported at 0.59/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corp go to 15.20%.

Boston Scientific Corp [BSX] Institutonal Ownership Details

There are presently around $93.65%, or 93.83%% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: FMR LLC with ownership of 141.46 million shares, which is approximately 9.6192%. VANGUARD GROUP INC, holding 129.87 million shares of the stock with an approximate value of $$10.0 billion in BSX stocks shares; and VANGUARD GROUP INC, currently with $$9.74 billion in BSX stock with ownership which is approximately 8.5964%.

DBT News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.